Moreover, the decreased sialylation levels of CLUS, CFH, and HEMO in serum of ovarian cancer patients were validated which showed that these biomarkers have potential utility for diagnosis of ovarian cancer with high accuracy [94]. This evidence concerns the gene CFH and ovarian cancer.